Health ❯ Medicine ❯ Pharmacology

Drug Development

Cancer Treatment Baxdrostat Targeted Therapies Targeted Therapy Weight Loss Drugs Protein Degradation Alzheimer's Disease Antibiotics Clinical Trials Male Contraceptives

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

The webcast will deliver the first Phase 3 readout for azetukalner in focal onset seizures.

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

Restoring NAD+ Reverses Alzheimer’s Signs in Mice, Study Finds

Researchers Engineer ‘Mild’ Mitochondrial Uncouplers in Preclinical Study

Approved Lymphoma Drug Helps Overcome Resistance in Neuroblastoma Models

Immune Cell Stress Switch Implicated in Chemo Neuropathy, With Existing Inhibitors Poised for Tests

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

Roche’s Oral BTK Drug Succeeds in Phase 3 MS Trials, Matching Ocrevus in Progressive Disease

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Nature Study Shows Intracellular GPCR Targeting Can Direct Signaling

FDA Clears UCLA’s ENPP1-Blocking Antibody AD-NP1 for First-in-Human Trial

AstraZeneca’s Baxdrostat Hits Phase 3 Goal With 24‑Hour Blood‑Pressure Cuts

UC Researchers Target Hsp70 to Counter Pancreatic Cancer Immunosuppression With Preclinical Nanovesicle Therapy

EMA Rejects Claim That Prenatal Paracetamol Causes Autism

Duke Study Shows Pancreatic Alpha Cells Produce Bioactive GLP-1

Freezing Brain Matrix Molecule Stops Glioblastoma Cells From Spreading in Lab

AstraZeneca’s Baxdrostat Lowers Blood Pressure in Phase III, Setting Up 2025 Filings

Peer-Reviewed OU Study Maps Amylin Receptors, Offering Tools for Next‑Gen Obesity Drugs

Repurposed Parkinson’s Drug Shows Promise as Host-Directed TB Therapy